Sonesitatug Vedotin not checked

AstraZeneca · AZD0901 · CMG901

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
6 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)”In the company’s words, NCT06346392 on ClinicalTrials.gov
Tested for
Gastric Cancer (5 trials), Gastroesophageal Junction Cancer (3 trials), Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Main trialPhase 3
“The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.”In the company’s words, NCT06346392 on ClinicalTrials.gov
Other names
AZD0901 · CMG901

Other drugs for Gastric Cancer

All 208 drugs for Gastric Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 May 2026 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3Recruiting 16 Aug 2029 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 2Active, not recruiting 14 Aug 2026 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Phase 2Recruiting 17 Nov 2026 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2Recruiting 9 Nov 2027 A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Phase 2Recruiting 30 Nov 2027 Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Sonesitatug Vedotin

Following is part of Solo: you see every change to Sonesitatug Vedotin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in